Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Commentary

Evaluation and management of atherogenic dyslipidemia: beyond low-density lipoprotein cholesterol

Jean-Pierre Després, Isabelle Lemieux, Gilles R. Dagenais, Bernard Cantin and BenoÎt Lamarche
CMAJ November 13, 2001 165 (10) 1331-1333;
Jean-Pierre Després
Dr. Després, Ms. Lemieux, Dr. Dagenais and Dr. Cantin are with the Quebec Heart Institute, Laval Hospital Research Centre, Sainte-Foy, Que. Dr. Després, Ms. Lemieux, and Dr. Lamarche are with the Lipid Research Centre, CHUL Research Centre, Sainte-Foy, Que.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Isabelle Lemieux
Dr. Després, Ms. Lemieux, Dr. Dagenais and Dr. Cantin are with the Quebec Heart Institute, Laval Hospital Research Centre, Sainte-Foy, Que. Dr. Després, Ms. Lemieux, and Dr. Lamarche are with the Lipid Research Centre, CHUL Research Centre, Sainte-Foy, Que.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gilles R. Dagenais
Dr. Després, Ms. Lemieux, Dr. Dagenais and Dr. Cantin are with the Quebec Heart Institute, Laval Hospital Research Centre, Sainte-Foy, Que. Dr. Després, Ms. Lemieux, and Dr. Lamarche are with the Lipid Research Centre, CHUL Research Centre, Sainte-Foy, Que.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernard Cantin
Dr. Després, Ms. Lemieux, Dr. Dagenais and Dr. Cantin are with the Quebec Heart Institute, Laval Hospital Research Centre, Sainte-Foy, Que. Dr. Després, Ms. Lemieux, and Dr. Lamarche are with the Lipid Research Centre, CHUL Research Centre, Sainte-Foy, Que.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
BenoÎt Lamarche
Dr. Després, Ms. Lemieux, Dr. Dagenais and Dr. Cantin are with the Quebec Heart Institute, Laval Hospital Research Centre, Sainte-Foy, Que. Dr. Després, Ms. Lemieux, and Dr. Lamarche are with the Lipid Research Centre, CHUL Research Centre, Sainte-Foy, Que.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading

The association between plasma level of low-density lipoprotein cholesterol (LDL-C) and the risk of coronary artery disease (CAD) is beyond dispute. As emphasized in the recently updated Canadian guidelines for the management and treatment of dyslipidemia,1 a variety of major clinical trials over the past decade have reported that lowering LDL-C levels has a clear benefit in reducing the risk of CAD events. Although significant, the risk reduction afforded by pharmacologic lowering of LDL-C has generally been limited to 30%.2 In addition, prospective studies such as the Quebec Cardiovascular Study3 have reported marked overlap in the distribution of LDL-C levels at baseline between men who went on to experience CAD and those who remained asymptomatic over the 5-year follow-up period. Thus, additional factors must modulate the risk of CAD associated with LDL-C. As recognized in the guidelines,1 established risk factors such as type 2 diabetes, older age, high blood pressure and smoking substantially increase the risk of CAD for any given level of LDL-C. Low level of high-density lipoprotein cholesterol (HDL-C), which is included in the Framingham algorithm for predicting multivariate CAD risk, is also a well-recognized risk factor,4 and there may be others as well.

The Working Group on Hypercholesterolemia and Other Dyslipidemias1 now considers diabetic patients over the age of 30 to be at very high risk for CAD and suggests that management of lipid level and blood pressure should be high priorities in their care. For nondiabetic people, the Working Group recommends the Framingham algorithm, which considers age, total cholesterol level, HDL-C level, systolic blood pressure and smoking status, for assessment of CAD risk. The guidelines also propose target values for LDL-C, total cholesterol:HDL-C ratio and triglycerides according to the level of risk estimated by the algorithm.

A new aspect of the guidelines was their emphasis on the “metabolic syndrome,” a cluster of risk factors including insulin resistance, elevated plasma triglyceride concentrations, low HDL-C levels and presence of small, dense LDL.1 The importance of the metabolic syndrome in terms of both prevalence and risk of CAD was also recognized in the recently published recommendations of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (also known as the Adult Treatment Panel).5 Unfortunately, this highly prevalent atherogenic condition is not currently considered in the Framingham algorithm. To illustrate the potential impact of the metabolic syndrome, we can review the example of a 53-year-old nonsmoking, nondiabetic male who is abdominally obese (waist circumference 101 cm), hypertriglyceridemic (triglyceride level 2.4 mmol/L) and normotensive (blood pressure 124/76 mm Hg). According to the Framingham algorithm, his age counts for 3 risk points. His HDL-C level is low (0.70 mmol/L), which counts for 2 risk points, his total cholesterol level is 5.1 mmol/L, which counts for zero points, and his systolic blood pressure counts for zero points. The total is therefore 5 risk points, which translates to a 10-year risk of only 8%, well below the 14% average risk reported for this age category.4 On the basis of the risk determined by the Framingham algorithm, the recommended target levels for this patient would be as follows: LDL-C below 5.0 mmol/L, total cholesterol:HDL-C ratio below 7.0 and triglyceride below 3.0 mmol/L. However, the risk of CAD may actually be much higher for this abdominally obese man, who has the features of the metabolic syndrome.

We have shown that asymptomatic men with elevated waist circumference and moderate hypertriglyceridemia6 are characterized by an atherogenic triad of metabolic abnormalities (hyperinsulinemia, elevation of apolipoprotein B and small, dense LDL particles) that substantially increases their risk for CAD, even in the absence of elevated cholesterol, elevated LDL-C and other traditional risk factors.7 Because of low HDL-C levels, the total cholesterol:HDL-C ratio of these abdominally obese, insulin-resistant men is often elevated to 7 or more. Data from the Quebec Cardiovascular Study8 indicate that elevation of the ratio to this level may be associated with an increased risk of CAD, even in the absence of elevated LDL-C levels. When the men in the Quebec Cardiovascular Study were stratified into tertiles according to baseline total cholesterol:HDL-C ratio and were further classified on the basis of median LDL-C level, there was a clear relation between total cholesterol:HDL-C ratio and risk of CAD, irrespective of LDL-C level (Table 1). Indeed, despite a highly significant difference in LDL-C (more than 1.0 mmol/L) between men below and those at or above the median LDL-C level, there was no significant difference in risk of CAD between these 2 groups, for any category of total cholesterol:HDL-C ratio (Table 1). Thus, because our 53-year-old man with abdominal obesity had the features of the metabolic syndrome (hyperinsulinemia, elevated apolipoprotein B concentrations and small, dense LDL), we could predict from this cluster a substantially increased risk of CAD despite an apparently low risk estimated from the Framingham algorithm. Futhermore, had the total cholesterol:HDL-C ratio (7.3) alone been considered, we would have predicted at least a 2.4-fold increase in the patient's risk of CAD (Table 1).

View this table:
  • View inline
  • View popup
  • Download powerpoint

Table 1.

These results further emphasize the importance of calculating the total cholesterol:HDL-C ratio and making it a therapeutic target.1 However, they also remind us that, irrespective of whether LDL-C level is elevated, a high total cholesterol:HDL-C ratio indicates higher risk of CAD. Elevation of the total cholesterol:HDL-C ratio in the absence of marked elevation of LDL-C level is a salient feature of insulin-resistant, abdominally obese patients, as well as of type 2 diabetic patients, most of whom are abdominally obese.6 Among men in the top tertile for total cholesterol:HDL-C ratio (ratio at least 6.4), there was a high prevalence of the metabolic syndrome (almost 40%), but there was no difference in the prevalence of this syndrome between subjects with low and high LDL-C levels (Table 2). Furthermore, the group with elevated total cholesterol:HDL-C ratio but low LDL-C level had a higher prevalence of obesity (defined as body mass index of at least 30) than those with elevation of both total cholesterol:HDL-C ratio and LDL-C levels (26.2% v. 13.5%). Thus, elevation of the total cholesterol:HDL-C ratio is often accompanied by an underlying metabolic syndrome resulting from obesity, a condition that may not be associated with elevated LDL-C level. We acknowledge that pharmacotherapy aimed at lowering LDL-C is legitimate; however, given that the risk of CAD associated with elevation of the total cholesterol:HDL-C ratio does not vary substantially with LDL-C level, we propose that more attention should be paid to the management of the causal factor responsible for atherogenic dyslipidemia in these patients: abdominal obesity. Therefore, we recommend that waist circumference, the best and simplest correlate of abdominal obesity,6 be measured and recorded for these patients. Furthermore, given that the Veterans Affairs High Density Lipoprotein Intervention Trial9 has reported the benefits of therapy to increase HDL-C among diabetic and abdominally obese hyperinsulinemic patients, strong efforts should be made to reduce waist girth and increase HDL-C levels in these high-risk “normocholesterolemic” patients. Reducing body weight by reducing the caloric density of foods consumed (i.e., less fat and refined sugar) and increasing energy expenditure through a more active lifestyle thus appear to be legitimate objectives for better management of propensity for CAD in high-risk patients with the metabolic syndrome.

View this table:
  • View inline
  • View popup
  • Download powerpoint

Table 2.

Finally, the pharmacologic agents that are available to induce significant weight loss10,11 have been tested primarily in women at low risk of CAD.12 Despite the increasing recognition of abdominal obesity as the most prevalent cause of the atherogenic metabolic syndrome, randomized trials are urgently needed to verify whether pharmacotherapy targeted to abdominal obesity is effective in preventing CAD events and related deaths.

Acknowledgments

Dr. Després is chair professor of human nutrition and lipidology, a position supported by Pfizer, Provigo and the Foundation of the Quebec Heart Institute. Ms. Lemieux is the recipient of a studentship from the Heart and Stroke Foundation of Canada. Dr. Dagenais is professor emeritus at Université de Montréal and Université Laval. Dr. Cantin is currently a research fellow of the Canadian Institutes of Health Research (CIHR) at Stanford University. Dr. Lamarche is chair professor of nutrition, functional foods and cardiovascular health through the Canada Research Chair program at Université Laval. This work was supported by the CIHR (grants MT-14014 and MGC-15187).

Footnotes

  • This article has been peer reviewed.

    Competing interests: None declared.

References

  1. 1.↵
    Fodor JG, Frohlich JJ, Genest JJ Jr, McPherson PR. Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias. CMAJ 2000; 162:1441-7. Available: www.cma.ca/cmaj/vol-162/issue-10/1441.htm
    OpenUrlFREE Full Text
  2. 2.↵
    LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary heart disease: a meta-analysis of randomized controlled trials. JAMA 1999;282:2340-6.
    OpenUrlCrossRefPubMed
  3. 3.↵
    Després JP, Lemieux I, Dagenais GR, Cantin B, Lamarche B. HDL-cholesterol as a marker of coronary heart disease risk: the Québec cardiovascular study. Atherosclerosis 2000;153:263-72.
    OpenUrlCrossRefPubMed
  4. 4.↵
    Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
    OpenUrlCrossRefPubMed
  6. 6.↵
    Lemieux I, Pascot A, Couillard C, Lamarche B, Tchernof A, Alméras N, et al. Hypertriglyceridemic waist: A marker of the atherogenic metabolic triad (hyperinsulinemia, hyperapolipoprotein B, small, dense LDL) in men? Circulation 2000;102:179-84.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    Lamarche B, Tchernof A, Mauriège P, Cantin B, Dagenais GR, Lupien PJ, et al. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 1998;279:1955-61.
    OpenUrlCrossRefPubMed
  8. 8.↵
    Lemieux I, Lamarche B, Couillard C, Pascot A, Cantin B, Dagenais GR, et al. Cholesterol/HDL cholesterol ratio vs. LDL cholesterol/HDL cholesterol ratios as indices of IHD risk in men: the Quebec Cardiovascular Study. Arch Intern Med. In press.
  9. 9.↵
    Robins S, Collins D, Rubins HB. Diabetes, hyperinsulinemia and recurrent coronary events in the VA-High Density Lipoprotein Intervention Trial (VA-HIT) [abstract]. Circulation 2000;102:II-847.
  10. 10.↵
    Sjöström L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998;352:167-72.
    OpenUrlCrossRefPubMed
  11. 11.↵
    James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000;356:2119-25.
    OpenUrlCrossRefPubMed
  12. 12.↵
    Després JP, Lemieux I, Prud'homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ 2001;322:716-22
    OpenUrlFREE Full Text
PreviousNext
Back to top

In this issue

CMAJ
Vol. 165, Issue 10
13 Nov 2001
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Evaluation and management of atherogenic dyslipidemia: beyond low-density lipoprotein cholesterol
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Evaluation and management of atherogenic dyslipidemia: beyond low-density lipoprotein cholesterol
Jean-Pierre Després, Isabelle Lemieux, Gilles R. Dagenais, Bernard Cantin, BenoÎt Lamarche
CMAJ Nov 2001, 165 (10) 1331-1333;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Evaluation and management of atherogenic dyslipidemia: beyond low-density lipoprotein cholesterol
Jean-Pierre Després, Isabelle Lemieux, Gilles R. Dagenais, Bernard Cantin, BenoÎt Lamarche
CMAJ Nov 2001, 165 (10) 1331-1333;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Comparison between Gradient Gel Electrophoresis and Nuclear Magnetic Resonance Spectroscopy in Estimating Coronary Heart Disease Risk Associated with LDL and HDL Particle Size
  • Risk factors for cardiovascular disease
  • Google Scholar

More in this TOC Section

  • Time for a regulatory framework for pediatric medications in Canada
  • Optimizing timing of completion of the Surgical Safety Checklist to account for emergence from anesthesia
  • Shifting from cytology to HPV testing for cervical cancer screening in Canada
Show more Commentary

Similar Articles

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2022, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire